Liujia Qian received her bachelor’s degree in biomedicine and pharmacy from Huazhong University of Science and Technology (2012-2016), her master’s degree in microbiology and biochemical pharmacy from Shanghai Institute of Pharmaceutical Industry (2016-2019), and her PhD in basic medical sciences from Zhejiang University-Westlake University (2019-2023). Her research primarily focuses on clinical proteomics, with major studies on ovarian cancer, lung cancer, and COVID-19. By conducting proteomic preprocessing and analysis of thousands of tumor tissue and blood samples, combined with artificial intelligence, she aims to elucidate the molecular mechanisms underlying diseases and identify biomarkers for differential diagnosis and prognosis. Currently, she serves as a research associate at the Laboratory of Complex Proteomics and Science, Westlake University, where she focuses on the development of an AI-based Virtual Cell (AIVC) model using perturbed proteomics.

Representative Publications

1.Nie, X.#, Qian, L. #, Sun, R. #, Huang, B. #, Dong, X. #, Xiao, Q. #, Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021). Multi-organ proteomic landscape of COVID-19 autopsies. Cell 184, 775-791 e714. (#, co-first author)
2. Liujia Qian#, Jianqing Zhu#, Zhangzhi Xue#, Yan Zhou#, Nan Xiang#, Hong Xu#, et al. (2024). Proteomic landscape of epithelial ovarian cancer. Nat Commun 15(1):6462. (#, co-first author).
3.Qian, L., and Guo, T. (2021). Immunometabolism the CyTOF way. Immunity 54, 610-613.
4.Luo, X. #, Qian, L. #, Xiao, Y., Tang, Y., Zhao, Y., Wang, X., Gu, L., Lei, Z., Bao, J., Wu, J., et al. (2019). A diversity-oriented rhodamine library for wide-spectrum bactericidal agents with low inducible resistance against resistant pathogens. Nat Commun 10, 258. (#, co-first author).